(Q43272350)

English

Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease

scientific article published on 23 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 November 2017

Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease (English)

1 reference

Europe PubMed Central

18 November 2017

1 reference

based on heuristic

inferred from title

author name string

Ming Wu

1

1 reference

Europe PubMed Central

18 November 2017

Alexandre Arcaro

2

1 reference

Europe PubMed Central

18 November 2017

Zsuzsanna Varga

3

1 reference

Europe PubMed Central

18 November 2017

Alexander Vogetseder

4

1 reference

Europe PubMed Central

18 November 2017

Michel Le Hir

5

1 reference

Europe PubMed Central

18 November 2017

Rudolf P Wüthrich

6

1 reference

Europe PubMed Central

18 November 2017

Andreas L Serra

7

1 reference

Europe PubMed Central

18 November 2017

publication date

23 September 2009

1 reference

Europe PubMed Central

18 November 2017

American Journal of Physiology - Renal Physiology

1 reference

Europe PubMed Central

18 November 2017

297

1 reference

Europe PubMed Central

18 November 2017

6

1 reference

Europe PubMed Central

18 November 2017

F1597-605

1 reference

Europe PubMed Central

18 November 2017

Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Insulin reduces apoptosis and increases DNA synthesis and cell size via distinct signalling pathways in Drosophila Kc cells

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Regulation of translation initiation by FRAP/mTOR

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Rat models of autosomal dominant polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

mToR inhibitors-induced proteinuria: mechanisms, significance, and management

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Potential pharmacological interventions in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

mTOR and cancer: insights into a complex relationship

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Atubular glomeruli in a rat model of polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00430.2009

21 January 2018

Identifiers

10.1152/AJPRENAL.00430.2009

1 reference

Europe PubMed Central

18 November 2017

1 reference

Europe PubMed Central

18 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43272350&oldid=1985261691"